On October 25, 2023, during the 2023 Boehringer Ingelheim China R&D Day event, Burning Rock and Boehringer Ingelheim officially signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics. This agreement aims to provide Chinese...
2023
2023
2022
2021
2020
Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test
GUANGZHOU, China, Oct. 15, 2023 -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for its...
Burning Rock announced a China collaboration with AstraZeneca
On August 9, 2023, Burning Rock (NASDAQ/LSE: BNR) announced a China collaboration with AstraZeneca (NASDAQ/LSE/STO: AZN). As part of the collaboration, Burning Rock will leverage its leading detection technologies and high-quality, standardized testing capabilities to...
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
IRVINE, Calif. Jan.03, 2023 - Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been...